New Dual Monoclonal ELISA for Measuring Plasma Osteopontin as a Biomarker Associated with Survival in Prostate Cancer: Clinical Validation and Comparison of Multiple ELISAs
New Dual Monoclonal ELISA for Measuring Plasma Osteopontin as a Biomarker Associated with Survival in Prostate Cancer: Clinical Validation and Comparison of Multiple ELISAs
复制标题
DOI：
10.1373/clinchem.2008.117465
复制
发表时间：
2009-05-01
影响因子：
9.3
通讯作者：
Chambers, Ann F.
中科院分区：
文献类型：
--
作者：
Anborgh, Pieter H.;Wilson, Sylvia M.;Chambers, Ann F.
背景技术背景：先前开发的检测骨桥蛋白（OPN）血浆浓度的单克隆/多克隆ELISA（Mono/Poly）显示可提供乳腺癌、前列腺癌和其他癌症的预后信息。在这里，我们描述了一种新的双单克隆（双单）检测的临床验证。我们将两种检测方法与识别OPN蛋白确定区域的4种检测方法（双多克隆系统5-1、4-1、4-3和多克隆-单克隆系统1-3）进行比较。使用6 ELISA，我们测量OPN在血浆中从66例去势抵抗性前列腺癌，我们评估了每一个分析的能力，以预测患者survival.RESULTS：测定不同的血浆OPN浓度，中位数值范围从112到1740 μ g/L，并能够预测患者的生存。通过OPN三分位数生存期的考克斯单变量回归，单/多和双单ELISA具有最高的对数秩卡方检验值。在我们的样本中，调整了与生存独立相关的风险因素后，OPN仅在Mono/Poly和Dual Mono system.CONCLUSIONS：OPN血浆值根据所用的测定方法显著变化。在去势抵抗性前列腺癌男性人群中，只有Mono/Poly和Dual Mono系统与生存率独立相关。临床验证的双单克隆ELISA的可用性将为癌症和其他病理学中OPN血浆浓度的研究提供一致的试剂。(C)2009年美国临床化学协会
BACKGROUND: A previously developed monoclonal/polyclonal ELISA (Mono/Poly) to detect plasma concentrations of osteopontin (OPN) was shown to provide prognostic information in breast, prostate, and other cancers. Here we describe the clinical validation of a new dual monoclonal (Dual Mono) assay. We compared both assays with 4 assays that recognize defined regions of OPN protein (dual polyclonal systems 5-1, 4-1, 4-3 and polyclonal-monoclonal system 1-3).METHODS: OPN sequences recognized by the monoclonal antibodies that make up the Dual Mono ELISA were identified by Pepscan CLIPS (TM) analysis. Using the 6 ELISAs, we measured OPN in plasma from 66 patients with castration-resistant prostate cancer, and we assessed the ability of each assay to predict patient survival.RESULTS: The assays varied in measured plasma OPN concentrations, with median values ranging from 112 to 1740 mu g/L, and ability to predict patient survival. By Cox univariable regression of survival by tertiles of OPN, the Mono/Poly and Dual Mono ELISAs had the highest log-rank chi(2) values. After adjustment for risk factors independently associated with Survival in our samples, OPN remained associated with Survival only for the Mono/Poly and Dual Mono systems.CONCLUSIONS: OPN plasma values varied significantly depending oil the assay used. Only the Mono/Poly and Dual Mono systems were independently associated with survival in a population of men with castration-resistant prostate cancer. The availability of a clinically validated, dual monoclonal-based ELISA will provide consistent reagents for studies of OPN plasma concentrations in cancer and other pathologies. (C) 2009 American Association for Clinical Chemistry